How do we facilitate more clinical trials - so that patients, doctors and companies in the Norwegian health care industry are all winners?
May 27th 2020, 5PM, there will be a digital meeting opening a good conversation on the basis of this big question.
Baldur Sveinbjørnsson, Chief Scientific Officer in Lytix Biopharma, will participate in a panel discussion after initial presentations.
The meeting is arranged by OCC (Oslo Cancer Cluster), LMI (Legemiddelindustrien) and NCS (Norwegian Cancer Society).
More information, and link to the meeting. (Only in Norwegian)